Dyadic Current Ratio 2006-2021 | DYAI

Dyadic current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Dyadic Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.03B $0.00B 7.95
2021-03-31 $0.03B $0.00B 10.79
2020-12-31 $0.03B $0.00B 18.32
2020-09-30 $0.03B $0.00B 18.12
2020-06-30 $0.03B $0.00B 20.58
2020-03-31 $0.03B $0.00B 28.90
2019-12-31 $0.04B $0.00B 22.44
2019-09-30 $0.04B $0.00B 28.55
2019-06-30 $0.04B $0.00B 26.21
2019-03-31 $0.04B $0.00B 32.42
2018-12-31 $0.04B $0.00B 50.32
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.05B $0.00B 64.52
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B 0.00
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B 0.00
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B 0.00
2013-06-30 $0.00B 0.00
2013-03-31 $0.01B $0.01B 0.98
2012-12-31 $0.01B $0.00B 2.92
2012-09-30 $0.01B $0.00B 4.48
2012-06-30 $0.00B 0.00
2012-03-31 $0.01B $0.00B 3.00
2011-12-31 $0.01B $0.00B 2.25
2011-09-30 $0.01B $0.00B 2.61
2011-06-30 $0.01B $0.01B 1.84
2011-03-31 $0.01B $0.00B 2.06
2010-12-31 $0.01B $0.00B 2.42
2010-09-30 $0.01B $0.00B 2.83
2010-06-30 $0.01B $0.01B 1.80
2010-03-31 $0.01B $0.01B 1.73
2009-12-31 $0.01B $0.01B 1.81
2009-09-30 $0.02B $0.00B 3.67
2009-06-30 $0.02B $0.00B 3.60
2009-03-31 $0.02B $0.01B 1.17
2006-12-31 $0.04B $0.00B 9.31
2006-09-30 $0.00B 0.00
2006-06-30 $0.00B 0.00
2006-03-31 $0.00B 0.00
2005-12-31 $0.02B $0.01B 4.59
2005-09-30 $0.02B $0.00B 6.60
2005-06-30 $0.03B $0.00B 7.36
2005-03-31 $0.03B $0.01B 6.02
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.122B $0.002B
Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms including humans found in the earth's biodiversity. Using its integrated technology platform, Dyadic develops biological products such as proteins, enzymes, polypeptides and small molecules for applications in large segments of the agricultural, industrial, chemical and biopharmaceutical industries. By utilizing a proprietary host organism, Dyadic's `one-stop shop` technology rapidly discovers and expresses eukaryotic genes the genes of complex living organisms and then manufactures those unique biological products for commercial application. Dyadic's systems overcome the inadequacy of existing gene discovery and product development techniques.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86